<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04524208</url>
  </required_header>
  <id_info>
    <org_study_id>02679</org_study_id>
    <nct_id>NCT04524208</nct_id>
  </id_info>
  <brief_title>A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3</brief_title>
  <acronym>CABONEN</acronym>
  <official_title>CABONEN - A Phase II Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karsten Gavenis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Goettingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this clinical trial represents the evaluation of efficacy of the&#xD;
      tyrosine kinase inhibitor Cabozantinib in patients with NEN G3 with a proliferation rate of&#xD;
      Ki67 20 - 60%.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of Cabozantinib treatment via DCR after 6 months.</measure>
    <time_frame>6 months</time_frame>
    <description>Disease control rate (DCR) 6 months after treatment start .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate short- and long term efficacy of Cabozantinib treatment via DCR.</measure>
    <time_frame>12 months</time_frame>
    <description>DCR 3 and 12 months after treatment start.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate short- and long term efficacy of Cabozantinib treatment via ORR.</measure>
    <time_frame>12 months</time_frame>
    <description>Objective response rate (ORR) 3, 6 and 12 months after treatment start and best objective response rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate short- and long term efficacy of Cabozantinib treatment via PFS.</measure>
    <time_frame>24 months</time_frame>
    <description>Progression free survival (PFS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate short- and long term efficacy of Cabozantinib treatment via OS.</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival (OS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate exposure time.</measure>
    <time_frame>12 months</time_frame>
    <description>Time on drug (TOD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess quality-of-life during and after Cabozantinib treatment.</measure>
    <time_frame>15 months</time_frame>
    <description>EORTC QLQ-C30 Quality of Life Questionnaire monthly for 12 months after treatment start and after 15 months. Different questions regarding Quality of Life on a scale of 1 - 4. The lower the numbers, the better the quality of Life.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of Cabozantinib via AE and SAE assessment.</measure>
    <time_frame>24 months</time_frame>
    <description>Adverse events and serious adverse events will be assessed in contingency tables.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Neuroendocrine Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment-Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>Cabozantinib is administered orally at the dose of 60 mg per day..</description>
    <arm_group_label>Treatment-Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with histologically confirmed diagnosis of neuroendocrine neoplasia;&#xD;
&#xD;
          2. Tumor proliferation rate has to be between Ki67 20% to 60% (local assessment);&#xD;
&#xD;
          3. Male, female, or diverse patients aged &gt; 18 years without upper age limit;&#xD;
&#xD;
          4. At least one measurable tumor lesions in CT or MRI scan;&#xD;
&#xD;
          5. Newly diagnosed or progressive disease assessed per RECIST criteria 1.1;&#xD;
&#xD;
          6. Patients must have a performance status of ECOG 0-2;&#xD;
&#xD;
          7. Patients must have a life expectancy of more than 3 months;&#xD;
&#xD;
          8. Hb&gt; 9 mg/dl;&#xD;
&#xD;
          9. platelets &gt;80T/µl;&#xD;
&#xD;
         10. white blood cells &gt;3T/μL;&#xD;
&#xD;
         11. total bilirubin &lt;3mg/dl;&#xD;
&#xD;
         12. AST and ALT &lt;4xN;&#xD;
&#xD;
         13. Serum creatinine &lt;2mg/dl, eGFR &gt;40mL/min/1.73m2;&#xD;
&#xD;
         14. BUN &lt;5xN;&#xD;
&#xD;
         15. lipase &lt;3xN;&#xD;
&#xD;
         16. albumin ≥2.8 g/dL;&#xD;
&#xD;
         17. PT/PTT ≤ 1.5 × ULN;&#xD;
&#xD;
         18. urine protein: creatinine ratio ≤ 1;&#xD;
&#xD;
         19. Written informed consent obtained according to international guidelines and local&#xD;
             laws;&#xD;
&#xD;
         20. Ability to understand the nature of the trial and the trial related procedures and to&#xD;
             comply with them;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients younger than 18 years;&#xD;
&#xD;
          2. Patients with Mixed Neuroendocrine-Non-neuroendocrine Neoplasia (MINEN);&#xD;
&#xD;
          3. Patients with former treatment with TKI or VEGF receptor antagonist;&#xD;
&#xD;
          4. Patients with additional malignancy &lt;5 years in medical history (exclusion:&#xD;
             non-invasive skin cancer);&#xD;
&#xD;
          5. Patients with symptomatic brain metastases;&#xD;
&#xD;
          6. Patients with Known HIV infection, infectious hepatitis (type A, B or C) or another&#xD;
             uncontrolled infection;&#xD;
&#xD;
          7. Patients with Known hypersensitivity to Cabozantinib or contraindications for&#xD;
             treatment with Cabozantinib according to Summary of Product Characteristics (SmPC);&#xD;
&#xD;
          8. Patients with class III or IV congestive heart failure;&#xD;
&#xD;
          9. Patients with QTc more than 500 ms or 140% of normal range according to age;&#xD;
&#xD;
         10. Patients with uncontrolled hypertension;&#xD;
&#xD;
         11. Patients with severely impaired lung function;&#xD;
&#xD;
         12. Patients with history of organ transplant (exclusion: cornea transplantation);&#xD;
&#xD;
         13. Patients with clinical apparent acute or chronic gastric ulceration;&#xD;
&#xD;
         14. Patients with history of hemophilia;&#xD;
&#xD;
         15. Patients with surgery at the GI tract within the last 12 weeks;&#xD;
&#xD;
         16. Patients with patients with uncontrolled inflammatory bowel disease;&#xD;
&#xD;
         17. Simultaneous participation in other interventional trials which could interfere with&#xD;
             this trial; simultaneous participation in registry and diagnostic trials is allowed&#xD;
&#xD;
         18. Patient without legal capacity who is unable to understand the nature, significance&#xD;
             and consequences of the trial;&#xD;
&#xD;
         19. Previous participation in this trial&#xD;
&#xD;
         20. concomitant use of therapeutic anticoagulation or strong CYP3A4 inducers or inhibitors&#xD;
             (e.g. amiodarone);&#xD;
&#xD;
         21. Known or persistent abuse of medication, drugs or alcohol;&#xD;
&#xD;
         22. Person who is in a relationship of dependence/employment with the sponsor or the&#xD;
             investigator;&#xD;
&#xD;
         23. Patients who cannot give informed consent;&#xD;
&#xD;
         24. Current or planned pregnancy, nursing period;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander König, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Göttingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Halfen, Dr.</last_name>
    <phone>+49 (0)511 39 62362</phone>
    <email>jessica.halfen@med.uni-goettingen.de</email>
  </overall_contact>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>August 21, 2020</last_update_submitted>
  <last_update_submitted_qc>August 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Goettingen</investigator_affiliation>
    <investigator_full_name>Karsten Gavenis</investigator_full_name>
    <investigator_title>Project Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

